COVID-19 Pandemic: A Case for Phytomedicines

Overview

Journal Nat Prod Commun

Publisher Sage Publications

Date 2021 Jun 30

PMID 34191921

Citations 18

Authors

Abidemi J Akindele

Foluso O Agunbiade

Margaret O Sofidiya

Olufunsho Awodele

Abimbola Sowemimo

Omobolanle Ade-Ademilua

Moshood O Akinleye

Ismail O Ishola

Ifeoma Orabueze

Olumuyiwa B Salu

Ibrahim A Oreagba

Olayinka T Asekun

Olukemi Odukoya

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) is an infection caused by a newly discovered coronavirus which was identified in Wuhan, China. The race is on globally to repurpose drugs for COVID-19 and develop a safe and effective vaccine against the disease. There is an urgent need to search for effective remedies against COVID-19 from the rich and extensive flora of Africa and the world. A literature search was conducted to obtain information on drugs with the potential for effectiveness in the treatment of COVID-19 based mostly on outcomes of preclinical studies and a few clinical investigations. This was considered important to this perspective as some of the identified mechanisms of action may be related to potential anti-COVID-19 actions of phytomedicines. The findings from the literature search were also used to establish the need for exploration of phytomedicines in the fight against COVID-19. This perspective identifies the need to preserve the rich tradition of herbal medicine in Africa, repositioning it by inculcating all aspects of discovery, development, and chemical evaluation of pharmaceuticals from medicinal plants for effective management of prevalent diseases. The identified mechanisms of action of current drugs under consideration for the treatment of COVID-19 include preventing fusion of SARS-CoV-2 with human cells; decrease acidity in endosomes, cell membrane-derived vesicles for transportation of the virus within the host cell and within which the virus can replicate; and blockade of the production of proinflammatory cytokines. Phytomedicines may possibly elicit either one or a combination of these effects. The case for the exploration of phytomedicines against COVID-19 is strengthened by the emergence of a number of conventional drugs from medicinal plants and the emergence of botanicals with proven efficacy for some medical conditions. Caution against indiscriminate use of medicinal plants in the guise of treating COVID-19 has been highlighted and the need for reliable preclinical and clinical studies.

Citing Articles

Impact of the COVID-19 pandemic on the in-hospital diagnostic pathway of breast and colorectal cancer in the Netherlands: A population-based study.

Wolfkamp W, Meijer J, van Hoeve J, van Erning F, de Geus-Oei L, de Hingh I Cancer Med. 2024; 13(1):e6861.

PMID: 38197670 PMC: 10807577. DOI: 10.1002/cam4.6861.

Functional Foods: A Promising Strategy for Restoring Gut Microbiota Diversity Impacted by SARS-CoV-2 Variants.

Banerjee A, Somasundaram I, Das D, Jain Manoj S, Banu H, Mitta Suresh P Nutrients. 2023; 15(11).

PMID: 37299594 PMC: 10255361. DOI: 10.3390/nu15112631.

Hepatic Models to Assess Herb-Drug Interactions: Approaches and Challenges.

N H, C M, T R M, S S, S N, K E M Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986508 PMC: 10058280. DOI: 10.3390/ph16030409.

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective.

Risener C, Woo S, Samarakoon T, Caputo M, Edwards E, Klepzig K Sci Rep. 2023; 13(1):1244.

PMID: 36690683 PMC: 9868516. DOI: 10.1038/s41598-023-28303-x.

Phytochemicals in the Prevention and Treatment of SARS-CoV-2-Clinical Evidence.

Bijelic K, Hitl M, Kladar N Antibiotics (Basel). 2022; 11(11).

PMID: 36421257 PMC: 9686831. DOI: 10.3390/antibiotics11111614.

References

Farnsworth N, Akerele O, Bingel A, Soejarto D, Guo Z . Medicinal plants in therapy. Bull World Health Organ. 1985; 63(6):965-81. PMC: 2536466. View

. Redeploying plant defences. Nat Plants. 2020; 6(3):177. PMC: 7091691. DOI: 10.1038/s41477-020-0628-0. View

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

Devaux C, Rolain J, Colson P, Raoult D . New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 55(5):105938. PMC: 7118659. DOI: 10.1016/j.ijantimicag.2020.105938. View

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

Tay M, Fraser J, Chan W, Moreland N, Rathore A, Wang C . Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013; 99(3):301-6. DOI: 10.1016/j.antiviral.2013.06.002. View

Wagstaff K, Sivakumaran H, Heaton S, Harrich D, Jans D . Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012; 443(3):851-6. PMC: 3327999. DOI: 10.1042/BJ20120150. View

Cohen M . Rosehip - an evidence based herbal medicine for inflammation and arthritis. Aust Fam Physician. 2012; 41(7):495-8. View

10.

EISENBERG D, Davis R, Ettner S, Appel S, Wilkey S, Van Rompay M . Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998; 280(18):1569-75. DOI: 10.1001/jama.280.18.1569. View

11.

Fischer 2nd W, Vetter P, Bausch D, Burgess T, Davey Jr R, Fowler R . Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infect Dis. 2017; 18(6):e183-e192. PMC: 6636351. DOI: 10.1016/S1473-3099(17)30677-1. View

12.

Gadano A, Gurni A, Carballo M . Argentine folk medicine: genotoxic effects of Chenopodiaceae family. J Ethnopharmacol. 2005; 103(2):246-51. DOI: 10.1016/j.jep.2005.08.043. View

13.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

14.

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

15.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H . Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. PMC: 7078228. DOI: 10.1038/s41421-020-0156-0. View

16.

Le T, Andreadakis Z, Kumar A, Roman R, Tollefsen S, Saville M . The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305-306. DOI: 10.1038/d41573-020-00073-5. View

17.

Kupferschmidt K, Cohen J . Race to find COVID-19 treatments accelerates. Science. 2020; 367(6485):1412-1413. DOI: 10.1126/science.367.6485.1412. View

18.

Caly L, Druce J, Catton M, Jans D, Wagstaff K . The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. PMC: 7129059. DOI: 10.1016/j.antiviral.2020.104787. View

19.

Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009; 53(8):3416-21. PMC: 2715625. DOI: 10.1128/AAC.01509-08. View

20.

Vincent M, Bergeron E, Benjannet S, Erickson B, Rollin P, Ksiazek T . Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2:69. PMC: 1232869. DOI: 10.1186/1743-422X-2-69. View